EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease

Bingjie Ye, Chengfu Xu

Clinical and Molecular Hepatology · 2026

DOI: 10.3350/cmh.2026.0218 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Bingjie Ye und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. Hauptthemen laut MEDLINE: Blood Platelets, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Key Research and Development Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and is closely linked to systemic metabolic disorders. In addition to their classical role in hemostasis, platelets are increasingly recognized as active regulators of inflammation and immune responses, yet their contribution to MASLD pathogenesis remains incompletely defined. This review synthesizes current knowledge on how metabolic disturbances and gut microbiota dysbiosis trigger platelet hyperactivation and intrahepatic recruitment. We examined the mechanisms by which activated platelets exacerbate steatosis, amplify inflammation through interactions with immune cells, promote fibrogenic remodeling through hepatic stellate cell activation, and contribute to hepatocarcinogenesis. In the context of MASLD-associated hepatocellular carcinoma, platelet involvement may occur through both inflammation/fibrogenic remodeling–mediated and direct tumor-regulatory mechanisms. Furthermore, the therapeutic potential of antiplatelet agents, particularly aspirin, in attenuating disease progression has been evaluated. We conclude that targeting platelet-related pathways may represent a promising therapeutic strategy to interrupt the interplay between metabolic dysfunction and liver injury in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsLiver NeoplasmsFatty LiverHumansInflammationCarcinoma, HepatocellularAnimalsAspirinHepatic Stellate CellsLiver CirrhosisPlatelet Aggregation InhibitorsLiver

Stichwörter der Autor:innen

AspirinMASHMASLDMetabolic dysfunctionPlatelets

Substanzen

AspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  • Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. xiaofu@zju.edu.cn.

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Ye, B., & Xu, C. (2026). Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0218

Vancouver

Ye B, Xu C. Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0218

BibTeX
@article{Ye2026,
  author = {Ye, Bingjie and Xu, Chengfu},
  title = {Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2026.0218}
}
Kostenlos starten →